Merck's injected version of its blockbuster cancer drug Keytruda could face a potential patent challenge from biotech ...

Both Merck & Co. and Halozyme are holding their ground in a freshly unveiled patent dispute surrounding the New Jersey pharma ...

The company has asked the U.S. patent office to reconsider patents that could prevent it from selling an update to Keytruda.

另一项进展是，JMP Securities在强劲的第四季度业绩超出预期后，维持Halozyme的"市场表现优于大盘"评级，将股票目标价提高至78美元。H.C.

The new formulation of Keytruda, currently under FDA review, is sparking conflict with Halozyme, which makes enzymes that ...

美国食品药品监督管理局 (FDA) 已授予 PYX-201 快速通道资格，这是一种首创抗体药物偶联物 (ADC)，用于治疗在接受铂类化疗和抗 PD- (L)1 抗体治疗后病情出现进展的 R/M HNSCC 成年患者。

Merck's newly developed injected version of its blockbuster cancer drug, Keytruda, may be at the center of a potential patent ...

Shares in pharmaceuticals giant Merck (MRK) weakened today on fears that a patent battle could jeopardize its plans to sell a ...

Merck (MRK) has been adjusting Keytruda to make it easier to use and to protect the company for after the U.S. patent protection runs out in ...

Merck’s Keytruda holds on to the top spot while AbbVie’s Humira—once the world’s top-selling drug—continues to cede its ...